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The Swiss Childhood Cancer Registry (SCCR) is the national 
population - based cancer registry for children and adolescents 
in Switzerland. New cancer diagnoses, clinical information, de-
tails on treatment and long-term follow-up (survival, second 
primary neoplasms, and late effects) have been registered in 
the SCCR since 1976. With many associated research projects 
and through close collaboration with clinicians it contributes 
to understanding the causes of cancer in children, improving 
follow-up care, and reducing late effects.
The SCCR is located at the Institute of Social and Preven-
tive Medicine (ISPM) at the University of Bern. It is operated 
jointly by the Swiss Paediatric Oncology Group (SPOG) and the 
University of Bern. Since 1976, all nine Swiss paediatric haema-
tology - oncology centres report newly diagnosed cases to the 
registry and send annual updates on clinical follow - up. Since 
2007, the SCCR also collects supplementary data from other 
sources, including cantonal cancer registries, other hospitals, 
pathology laboratories and the Swiss Federal Statistical Office 
(SFSO). As of 31st December 2018, data from of 12008 cases 
(diagnosed in 11850 patients) have been registered. Until now, 
it was not compulsory to register newly diagnosed cancer cases 
in the registry. From 1st of January 2020 this will change with the 
new federal law on cancer registration. 
The SCCR is authorized to collect non - anonymised data. 
The permission has been issued in 2007 by the Federal Com-
mission of Experts for Professional Secrecy in Medical Research 
(Eidgenössische Expertenkommission für das Berufsgeheimnis 
in der medizinischen Forschung). Since 2014 the new act on 
human research is in place. The SCCR got a new authorization 
issued by the ethics committee of the canton of Bern in July 
2014.
The SCCR is an associated member of the National In-
stitute for Cancer Epidemiology and Registration (NICER), of 
the European Network of Cancer Registries (ENCR) and of the 
International Association of Cancer Registries (IACR), and col-
laborates with childhood cancer registries throughout Europe.
What did the Swiss Childhood Cancer Registry achieve 
in more than 40 years?
 • Performed national childhood cancer surveillance of high 
quality; cancer registration will be compulsory in Switzer-
land from 1st of January 2020 onwards 
• Provided reliable statistical routine data including tumour, 
treatment, and late effects information
 • Established a competitive research platform
 • Gave competent ad hoc answers to health- , environmental- , 
  socio- , political- related questions
 • Cooperated closely with all paediatric oncologists, 
 • Established a strong network with Swiss parents organi-
sations
This ninth report covers the routine analyses of all chil-
dren diagnosed between 1st January 1976 and 31st December 
2018. Activities, research, and publications of the SCCR are 
described for the years 2018 to 2019. The report contains:
• An overview of the organisation and team of the SCCR, 
SPOG, and the participating paediatric haematology - 
  oncology centres (Chapter 2)
• A summary of the data collected in the registry up to 31st 
December 2018 (Chapter 3)
• A summary of current research of the SCCR (Chapter 4)
• A list of publications (Chapter 5)
Our website (www.childhoodcancerregistry.ch) contains 
further information, including past annual reports and scien-
tific publications.
We would like to thank all the children and their families, 
and all adolescent and adult childhood cancer survivors, for 
allowing us to collect their data. We also thank the physicians 
and clinical research coordinators of the Swiss Paediatric On-
cology Group for their excellent collaboration. Our thanks also 
go to the cantonal cancer registries, the National Institute for 
Cancer Epidemiology and Registration (NICER), the Swiss Fed-
eral Statistical Office (SFSO), the Federal Office of Public Health 
(FOPH), and the pathology laboratories for their cooperation. 
Finally, we thank our supporters for their generous contribu-
tions.
1. Introduction
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2. Organisation of the Swiss Childhood Cancer Registry
The Swiss Childhood Cancer Registry (SCCR) is a member of the Swiss Paediatric Oncology Group (SPOG) and is orga-
nised as a joint operation of the Institute of Social and Preventive Medicine (ISPM) at the University of Bern and the 
SPOG.
2.1 Institute of Social and Preventive Medicine (ISPM), University of Bern
Direction
Claudia Kuehni, Prof MD 1. Co-Head of SCCR claudia.kuehni@ispm.unibe.ch
Verena Pfeiffer, PhD 2. Co-Head of SCCR verena.pfeiffer@ispm.unibe.ch
 
Swiss Childhood Cancer Registry
Katharina Flandera Administration katharina.flandera@ispm.unibe.ch
Shelagh Redmond, PhD Diagnostic coding, Head data quality
Kiraly Ersebet, MD Diagnostic coding
Julia Ruppel  Diagnostic coding
Ben Spycher, PhD  Statistics
Erika Brantschen, MA  Data management 
Ursina Roder, MSc  Administration databases 
 
Trust Centre 
Meltem Altun Data management 
 
Informatics and database support 
Vitor Rocha Database support 
 
Research projects 
Ben Spycher, PhD  Head of Aetiology research group 
Fabiën Belle, PhD  Senior research fellow
Astrid Coste, PhD  Senior research fellow
Garyfallos Konstantinoudis, PhD Senior research fellow 
Christian Kreis, PhD  Senior research fellow
Christophe Folly, MSc  PhD student
Antonella Mazzei, MSc PhD student
Maria Otth, MD  PhD student
Christina Schindera, MD  PhD student 
Nicolas Waespe, MD  PhD student 
Swiss Childhood Cancer Registry
Institute of Social and
Preventive Medicine
Mittelstrasse 43
CH - 3012 Bern
Switzerland
Tel. +41 (0)31 631 56 70
www.childhoodcancerregistry.ch
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2.2 Swiss Paediatric Oncology Group (SPOG)
SPOG Executive Board 
Roland Ammann, Prof MD President
Felix Niggli, Prof MD     Previous president
Michael Grotzer, Prof MD Vice president
Maja Beck Popovic, Prof MD Assessor
Heinz Hengartner, MD Assessor 
SPOG Coordinating Center in Bern 
Isabelle Lamontagne - Müller, MSc Managing Director isabelle.lamontagne@spog.ch
Marlise Rohrer Assistant to Managing Director
Julia Ruckstuhl, MSc Head Clinical Operations
Patrizia Specker Partner Relations
Michael Zeller, PhD Team Leader Clinical Project Management 
Tu-My Diep Lai, PhD Clinical Project Management 
Lara Fux Clinical Project Management 
Derya Keller, MSc Clinical Project Management
Moritz Saxenhofer, PhD Clinical Project Management
Silvia Wirth, PhD Clinical Project Management
Eliane Briggen Administration Clinical Project Management
Chun Wai Samantha Chan, PhD Assistant Quality Management
 
Participating centres (paediatric haematology - oncology)
  Head of Division Clinical Research Coordinator
Aarau 
Kinderklinik, Kantonsspital Aarau K. Scheinemann, MD S. Drerup
Basel 
Universitäts - Kinderspital  N. von der Weid, Prof MD V. Stahel
beider Basel [UKBB]  M. Imbach
Bellinzona 
Reparto di Pediatria, Ospedale  P. Brazzola, MD P. Brazzola, MD
S. Giovanni, Bellinzona  P. Balestra
Bern 
Universitätsklinik für  J. Rössler, Prof MD N. Assbichler 
Kinderheilkunde, Inselspital  N. Beusch
   N. Amport
Genève 
Hôpital des Enfants, Hôpitaux  M. Ansari, Prof MD R. Lo Piccolo
Universitaires de Genève [HUG]  V. Mattiello, MD
Lausanne 
Service de Pédiatrie, Centre Hospitalier  M. Beck Popovic, Prof MD S. Blanc
Universitaire Vaudois [CHUV]  E. Lemmel
Luzern 
Kinderspital, Kantonsspital Luzern F. Schilling, MD H. Baumeler
   J. Garibay
St.Gallen 
Ostschweizer Kinderspital J. Greiner - Lang, MD F. Hochreutener
    A. Schiltknecht
Zürich  
Universitäts - Kinderspital, Zürich F. Niggli, Prof MD C. Althaus, MD
  M. Grotzer, Prof MD H. Markiewicz
   A. Reinberg
   B. Schwenke 
   R. Siegenthaler
SPOG Coordinating Center
Effingerstrasse 3
CH - 3008 Bern
Switzerland
Tel. +41 (0)31 389 91 89
www.spog.ch
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2.3 General information
Aims 
The Swiss Childhood Cancer Registry collects information 
on the diagnosis, treatment, and follow- up of children and ad-
olescents with cancer in Switzerland, and provides data for na-
tional and international statistics and research projects. 
It aims: 
• To collect representative, population- based data on 
cancer in children and adolescents in Switzerland (cancer 
incidence, prevalence, time trends, regional distribution, 
and survival rates)
• To document diagnostic evaluations, treatment, and 
participation in clinical trials
• To describe short- term and long- term prognosis 
  (mortality, morbidity, and quality of life) after cancer in 
childhood and adolescence
• To provide a research platform for clinical, epidemiologi-
cal, and basic research
It thus contributes to:
• Research into the aetiology of cancer in children and 
adolescents
• Planning of health services 
• Continuous improvement of treatment
• Identifying possible late effects of therapy, with the aim 
to diagnose and treat them early and prevent them in 
the future 
Inclusion criteria
The SCCR registers all children and adolescents aged 0 to 
20 years, resident or treated in Switzerland, diagnosed with:
• Acute and chronic leukaemias, including myelodysplastic 
syndrome
• Lymphomas
• Malignant solid tumours
• Central nervous system tumours (CNS), malignant and 
benign tumours 
• Langerhans cell histiocytosis (LCH), 
  Hemophagocytic lymphohistiocytosis (HLH) 
Since 2014 it also registers children and adolescents diagnosed 
with:
• Aggressive fibromatosis (ICD - O - 3M code 8821 /1)
• Benign /mature teratoma (ICD - O - 3M code 9080 /0)
• Mesoblastic nephroma (ICD - O - 3M code 8960 /1)
• Severe aplastic anaemia (ICD - 10 D61.9)
• Neoplasms of the liver, histologically proven, but no 
malformations
Children and adolescents who are not Swiss residents but 
are diagnosed or treated in Switzerland are registered, but they 
are excluded from analyses of incidence and survival.
Sources of data
 Data on children and adolescents with cancer are collect-
ed from several sources, including: 
• The nine Swiss centres for paediatric oncology and hae-
matology (Chapter 2.2)
• Other hospitals
• Cantonal cancer registries, united in the National Institute 
  for Cancer Epidemiology and Registration (NICER)
• The Swiss Federal Statistical Office (SFSO; Swiss mortality 
statistics)
• Pathology laboratories, Paul Scherrer Institute (PSI) 
Most children are reported by one of the nine Swiss centres 
for paediatric oncology and haematology. There, local clinical 
research coordinators complete forms for all newly diagnosed 
patients. Basic information on diagnosis is later completed with 
information on treatments, remissions, relapses, transplanta-
tions, and health outcomes. These forms are sent to the SCCR 
and information is entered into the database. Important medi-
cal documents (e.g. pathology reports) are scanned and stored 
electronically using a pseudonym. Paper copies are destroyed. 
Information on Swiss residency is validated through municipal 
population registers.
For the first five to ten years after diagnosis follow- up data 
is extracted annually from patients’ hospital records by the lo-
cal clinical research coordinators in all paediatric oncology and 
haematology centres (Chapter 3.3). To assess outcomes after 
the children have left the clinic, patients are contacted directly 
with a questionnaire and data is linked to mortality records 
(SFSO) and to records from cantonal cancer registries (Chapter 
4.2). Life status update is assessed through community reg-
istries. For children not treated in a paediatric oncology and 
haematology centre, clinical follow- up from hospitals is often 
not available, but long- term epidemiological follow- up is done 
via questionnaires and by assessment of second primary neo-
plasms and mortality as for the other patients, and life status 
update via community registries (Chapter 3.3).
Clinical database
 The current SCCR database was set up in 2007. The fol-
lowing information is routinely collected:
• Tumour diagnosis, date of diagnosis, morphology, topo-
  graphy, stage, metastases
• Other diagnoses (cancer- relevant pre- existing conditions)
• Relevant laboratory and clinical data
• Treatment (clinical trial participation, chemotherapy, radio- 
  therapy, surgical intervention, bone marrow transplanta-
tion) and treatment centres involved
• Follow- up data (changes of treatment, remissions, 
  relapses, survival /death, and cause of death)
• Late adverse outcomes (e.g. cardiovascular diseases, 
second primary neoplasms, and endocrine disorders) 
12
Trust centre
Since 2010, personal information (name and address) is 
stored in a separate database in the trust centre. The trust cen-
tre validates addresses, residence status, nationality, and vital 
status via community registers. This personal information is 
separated strictly from clinical information of the SCCR data-
base. The following data is collected: 
• Patient name, address of residence at time of diagnosis, 
  current address of residence
• Date of birth, sex, first language
• Country of residence and nationality at time of diagnosis
• Vital status and date of death
• Parental profession, parental date of birth
Tumour coding
 All tumours are coded according to the following interna-
tional classification systems (see appendix): 
• International Classification of Childhood Cancer, third 
edition (ICCC - 3) 
• International Classification of Diseases for Oncology, 
third edition (ICD - O - 3) 
• International Classification of Diseases and Related 
Health Problems, tenth revision (ICD - 10) 
In the annual report, the main diagnostic groups of the ICCC - 3 
are used: 
I.  Leukaemias, myeloproliferative diseases, and myelodys- 
 plastic diseases
II.  Lymphomas and reticuloendothelial neoplasms
III.  CNS and miscellaneous intracranial and intraspinal 
 neoplasms
IV.  Neuroblastoma and other peripheral nervous cell tumours
V.  Retinoblastoma
VI. Renal tumours
VII. Hepatic tumours
VIII. Malignant bone tumours
IX.  Soft tissue and other extraosseous sarcomas
X. Germ cell tumours, trophoblastic tumours, and 
 neoplasms of gonads
XI.  Other malignant epithelial neoplasms and malignant   
 melanomas
XII. Other specified and unspecified malignant neoplasms 
Langerhans cell histiocytosis (LCH), which is not included in 
ICCC - 3, is reported separately.
Data protection
In 2004, the SCCR received a special authorisation (Son-
derbewilligung) from the Swiss Federal Commission of Experts 
for Professional Secrecy in Medical Research. Starting from 
June 2007, a general authorization (Registerbewilligung) per-
mitted the data collection from paediatric cancer patients (chil-
dren and adolescents) throughout Switzerland after obtaining 
written, oral or silent consent. 
Since January 2014 the new Human Research Act and its 
three ordinances are in place. Out of those three ordinances, 
the ordinance on Human Research with the exception of Clin-
ical Trials provides the new framework for the SCCR. Instead 
of the Swiss Federal Commission of Experts for Professional 
Secrecy in Medical Research, data collection and storage by 
the SCCR now require an authorisation by the ethics commit-
tee of the canton of Bern. The general authorization (Regis-
terbewilligung) has been replaced in July 2014 by an approval 
from the ethics committee of the canton of Bern
 From January 2020 onwards all patients with childhood 
cancer are obliged to be registered by federal law. 
Funding
The SCCR thanks the following supporters for their finan-
cial contributions towards the daily operation and the con-
tinuous development of the registry. Supporters of scientific 
research of the SCCR are listed in Chapter 4.
Main funding sources 2017 /2018
• Schweizerische Konferenz der kantonalen Gesundheits- 
  direktoren und - direktorinnen (GDK)
• Swiss Paediatric Oncology Group (SPOG)
• University of Bern, Institute of Social and Preventive 
Medicine (ISPM)
• Krebsforschung Schweiz 
• Kinderkrebshilfe Schweiz 
Other funding sources 2017 /2018
• Federal Office of Public Health (through National Institute 
for Cancer Epidemiology and Registration [NICER])
• Research contribution NICER
• Kinderkrebs Schweiz
• Celgene GmbH
  (through Förderverein Schweizer Kinderkrebsregister)
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3.1 Overview
The SCCR registers all tumours diagnosed and treated in 
Switzerland, classified according to the ICCC - 3 and Langer-
hans cell histiocytosis (LCH) in patients aged 0 to 20 years at 
time of diagnosis. This annual report covers the time period 
from 1st January 1976 until 31st December 2018. The addition-
al rare disorders, which are registered since 2014 (see inclusion 
criteria under paragraph 2.3), have not been included in the 
following analyses. Incidence rates are calculated based on the 
number of primary neoplasms (cases). The number of cases 
slightly exceeds the number of patients because patients with 
more than one primary tumour diagnosed before age 20 years 
are counted separately for each new tumour. 
The section on routine analyses includes three chapters:
Chapter 3.2 presents data on all cases registered in the 
SCCR. This includes cases resident in Switzerland or abroad, 
who were diagnosed or treated in Switzerland. 
Chapter 3.3 presents data on cases resident in Switzer-
land, aged 0 to 14 years at diagnosis. This correspondents to 
the age group usually covered in international publications. 
Therefore, tables and figures can be compared with data from 
other countries. Because registration in Switzerland is more 
than 95% complete for this age range with estimated inci-
dence and survival rates close to their true value.
Chapter 3.4 presents data on cases resident in Switzer-
land, aged 15 to 20 years at diagnosis. Patients of this age 
group are treated in a large number and variety of clinics and 
therefore registration is less complete. Incidence rates cannot 
be calculated for this age group.
3.2 All cases registered in the SCCR (N = 12008)
This chapter describes data from all cases diagnosed 
1976-2018, resident in Switzerland or abroad, diagnosed or 
treated in Switzerland (N=12008).
Up to 31st December 2018, a total of 12008 cases classi- 
fiable according to the ICCC-3, or Langerhans cell histiocytosis 
(LCH), have been registered in the SCCR. These tumours were 
diagnosed in 11850 patients. Among these, 11690 patients 
had only one primary neoplasm, 156 patients had two primary 
neoplasms, and 4 patients had three primary neoplasms at age 
0-20 years. 
The SCCR started in 1976. Initially, only patients aged 0 
to 15 years who participated in clinical trials were registered. 
Non- trial patients have been included since 1982, resulting 
in a significant increase in the number registered. In the early 
1990s, the introduction of the first electronic database further 
increased case registration (Figure 1).
In the last five years (2014-2018), a total of 1690 newly 
diagnosed cases were registered; among them 1494 cases in 
Swiss residents (Table 1).
Swiss residents account for 10815 (90%) of all cases and 
foreign residents for 1193 (10%) cases (Table 2). Swiss resi- 
dents make up 33% (193/587) of all retinoblastoma patients, 
while foreign residents make up 67% (394/587) of these pa- 
tients. This is due to the international reputation of the Jules 
Gonin Hospital in Lausanne, which is the national centre for 
retinoblastoma treatment but also attracts many patients from 
abroad.
3. Routine Analyses
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Figure 1
Annual number of 
registered cases over time
Swiss and foreign residents, age 
at diagnosis 0- 14 years; period of 
diagnosis 1976- 2018; all diagnoses 
(ICCC- 3 or Langerhans cell 
histiocytosis); N= 8736
14
 
  Age at diagnosis (years)
 All ages (0 - 20) Children (0 - 14) Adolescents (15 - 20)
     n % n % n %
Switzerland 10815 90.1 7685 88.0 3130 95.7
Foreign countries 1193 9.9 1051 12.0 142 4.3
Europe 860 7.2 777 8.9 83 2.5
Neighbouring countries 437 3.6 378 4.3 59 1.8
Austria 13 0.1 13 0.1 0 0.0
France 155 1.3 116 1.3 39 1.2
Germany 82 0.7 79 0.9 3 0.1
Italy 185 1.5 169 1.9 16 0.5
Liechtenstein 2 0.0 1 0.0 1 0.0
Other European countries* 423 3.5 399 4.6 24 0.7
Middle East 46 0.4 37 0.4 9 0.3
North Africa 165 1.4 128 1.5 37 1.1
Other African countries 52 0.4 45 0.5 7 0.2
Other countries 70 0.6 64 0.7 6 0.2
Total   12008 100 8736 100 3272 100
Swiss and foreign residents, age at diagnosis 0-20 years; period of diagnosis 1976-2018; all diagnoses (ICCC-3 or Langer-
hans cell histiocytosis); N=12008
* Albania, Armenia, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Cyprus, Czechia, Estonia, Finland, Georgia,
 Greece, Hungary, Ireland, Kosovo, Latvia, Lithuania, Luxembourg, Moldova, Monaco, Montenegro, Netherlands, 
 North Macedonia, Norway, Poland, Portugal, Romania, Russia, Serbia, United Kingdom
Table 2 
Total number of cases 
registered in the SCCR, 
by country of residence
Table 1
Total number of 
cases registered in the 
SCCR, by period of 
diagnosis 
   All patients Swiss Foreign  
    residents residents
   Age at Age at Age at 
   diagnosis diagnosis diagnosis  
 Year of diagnosis (years) (years) (years)
   0 - 14 15 - 20 0 - 14 15 - 20 0 - 14 15 - 20
  1976-1983 1021 324 911 303 110 21
  1984-1988 897 338 781 314 116 24
  1989-1993 1036 369 891 344 145 25
  1994-1998 1059 408 943 385 116 23
  1999-2003 1081 402 995 386 86 16
  2004-2008 1091 477 973 458 118 19
  2009-2013 1238 577 1066 571 172 6
  2014-2018 1313 377 1125 369 188 8
  Total 8736 3272 7685 3130 1051 142
    
Swiss and foreign residents, age at diagnosis 0-20 years; period of diagnosis 1976-2018; all diagnoses (ICCC-3 or Langer-
hans cell histiocytosis); N=12008
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3.3 Swiss residents aged 0 - 14 years 
 at diagnosis (N = 7685)
This chapter reports on cases aged 0 - 14 years and resi-
dent in Switzerland at diagnosis with a tumour coded accord-
ing to ICCC - 3 or a Langerhans cell histiocytosis. Results for 
this age group can be compared directly to data from other 
countries. 
Diagnoses
The International Classification of Childhood Cancer (ICCC - 3) 
distinguishes 12 groups of cancers (Table 3). The most com-
mon are leukaemias (32% of all cancers), followed by tumours 
of the central nervous system (21%; especially brain tumours); 
and lymphomas (12%). Other cancers arise from embryonic 
tissue. These include neuroblastoma (7%) from primitive neu-
ral tissue, renal tumours (5%), hepatic tumours (1%), germ cell 
tumours (3%), and retinoblastoma (3%). 
Germ cell tumours may arise in the gonads (ovaries and 
testes), or in other sites, such as the brain (intracranial germ 
cell tumours). Soft tissue sarcomas (7%), and malignant bone 
tumours (4%) arise from abnormal connective tissue. Occa-
sionally, children also develop carcinomas such as melanomas 
or other rare tumours (3%). Langerhans cell histiocytosis (3%) 
is officially not counted as a malignant disease. But as children 
with this disease are treated similarly to those with cancer and 
in rare cases also die, they are recorded in the Swiss Childhood 
Cancer Registry. The relative frequency of the different tumour 
types varies with age (Table 3 and Figure 2). 
 All children By age at diagnosis (years)
  <1 1 - 4 5 - 9 10 - 14
Diagnosis      n % n % n % n % n %
 I Leukaemias, myeloproliferative diseases, 
  and myelodysplastic diseases    2457 32.0 113 14.7 1162 44.1 680 33.3 502 22.4
 II Lymphomas and reticuloendothelial neoplasms  927 12.1 24 3.1 144 5.5 267 13.1 492 22.0
 III Central nervous system neoplasms   1610 20.9 100 13.0 455 17.3 581 28.4 474 21.2
 IV Neuroblastoma and other 
  peripheral nervous cell tumours   513 6.7 218 28.3 232 8.8 41 2.0 22 1.0
 V Retinoblastoma     193 2.5 92 11.9 91 3.5 9 0.4 1 0.0
 VI Renal tumours     377 4.9 56 7.3 217 8.2 90 4.4 14 0.6
 VII Hepatic tumours     71 0.9 24 3.1 26 1.0 9 0.4 12 0.5
 VIII Malignant bone tumours    325 4.2 1 0.1 18 0.7 94 4.6 212 9.5
 IX Soft tissue and other extraosseous sarcomas  513 6.7 55 7.1 148 5.6 128 6.3 182 8.1
 X Germ cell tumours, trophoblastic tumours, 
  and neoplasms of gonads    206 2.7 41 5.3 45 1.7 30 1.5 90 4.0
 XI Other malignant epithelial neoplasms 
  and malignant melanomas    247 3.2 4 0.5 11 0.4 49 2.4 183 8.2
 XII Other specified and unspecified malignant 
  neoplasms      18 0.2 2 0.3 4 0.2 2 0.1 10 0.4
  Langerhans cell histiocytosis    228 3.0 40 5.2 80 3.0 64 3.1 44 2.0
 Total      7685 100 770 100 2633 100 2044 100 2238 100
Swiss residents; age at diagnosis 0-14 years; period of diagnosis 1976-2018; all diagnoses (ICCC-3 or Langerhans cell histiocytosis); N=7685 
Table 3 - Main diagnostic groups according to ICCC-3, by age at diagnosis 
16
Swiss residents; age at diagnosis 0 - 14 years; period of diagnosis 1976 - 2018; all diagnoses (ICCC - 3 or Langerhans cell histiocytosis); 
N = 7685
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Langerhans cell histiocytosis
Follow- up information
The SCCR collects follow- up information for patients in several 
ways: 
1. Clinical follow- up is any contact the patient has with 
the paediatric oncology and haematology centre. Annual 
clinical follow- up care in paediatric centres usually ends 
5 - 10 years after diagnosis. Then the patient is officially 
discharged or referred to an adult oncology centre. Alter-
natively clinical follow- up also ends as soon as the patient 
dies. 
2. Long- term epidemiological follow- up for vital status, 
subsequent neoplasms, and current health employs four 
complementary approaches:
• Vital status and current address and place of birth are 
updated by contacting municipal population registers. 
Vital status is known for most cases: among the 7566 
patients, 1829 (24%) have died, and 5737 (76%) are still 
alive (Table 4). Among these, most (4295) have been fol-
lowed-up during the past 5 years, 939 (12%) have last 
been followed up between 2009 and 2013, and only 503 
(7%) before 2009. Among the latter, 122 (43 between 
2009-2013 and 79 before 2009) are lost to follow-up, 
because they moved abroad. 
• Causes of death are retrieved from Swiss mortality sta-
tistics by record linkage.
• Second primary neoplasms are notified via paediatric 
oncology and haematology centres, detected by regular 
comparison with cantonal (regional) cancer registries in 
Switzerland, or self- reported by survivors and then vali-
dated with pathology reports.
• Morbidity and quality of life are assessed by paper 
questionnaires to survivors in the Swiss Childhood Can-
cer Survivor Study and Childhood Cancer Follow- up 
Study (Chapter 4.2).
Table 4 - Follow- up information available in the SCCR
    n %
Alive  5737 75.8
Last clinical follow-up 2014-2018 4295 56.8
Last clinical follow-up 2009-2013 939 12.4
Last clinical follow-up before 2009 503 6.6
Deceased  1829 24.2
Total  7566 100.0
Swiss residents; age at diagnosis 0-14 years; period of diagnosis 1976-2018; all di-
agnoses (ICCC-3 or Langerhans cell histiocytosis); N= 7566 patients (7685 cases) 
Figure 2 
Main diagnostic groups according to ICCC - 3, by age at diagnosis
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Figure 3 
Survival of patients in the SCCR, 
by period of diagnosis
Swiss residents; age at diagnosis 0-14 years; 
period of diagnosis 1976-2018; all diagnoses 
(ICCC-3 or Langerhans cell histiocytosis); 
N=7685; adjusted for age.
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Figure 4 
Survival of patients by diagnostic 
groups according to ICCC - 3
Swiss residents; age at diagnosis 0-14 years; 
period of diagnosis 1999-2018 all diagnoses 
(ICCC-3 or Langerhans cell histiocytosis); 
N=4112; adjusted for age.
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Long- term survival has improved significantly over the last 
decades (Figure 3).
Ten-year survival increased from 62% in children diag- 
nosed between 1976 and 1988, to 73% in children diagnosed 
between 1989-1998, 84% in children diagnosed between 
1999 and 2008, and 87% in children diagnosed within the last 
decade (2009-2018). 
Survival varied widely between diagnostic groups. Figure 4 
presents survival by diagnostic group according to ICCC-3 in 
children diagnosed between 1999 and 2018. Of 4112 chil- 
dren, 645 (16%) have died. The following numbers describe 
five-year survival for each main diagnostic group: 100% for 
Langerhans cell histiocytosis; 98% for retinoblastoma; 95% for 
germ cell tumours; 95% for lymphoma; 94% for renal tumours; 
87% for children with leukaemia; 80% for hepatic tumours; 
78% for neuroblastoma; 78% for soft tissue sarcomas; 74% 
for central nervous system neoplasms, and 73% for malignant 
bone tumours.
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Cancer incidence (2009 - 2018) in Switzerland, 
for children aged 0 - 14 years at diagnosis
Table 5 describes the tumours registered in the SCCR 
during the last ten years (2009-2018). Diagnoses are coded 
according to ICCC-3.
The age-standardised incidence (according to the Euro-
pean standard population) of any childhood cancer (not in-
cluding Langerhans cell histiocytosis) was 17,3 per 100‘000 
person-years. Incidence was highest among children aged 2 
years with 24,8 cases per 100‘000 person-years (boys 28,9, 
girls 20,5). Incidence was lowest in 9 year olds with 11,6 cases 
per 100‘000 person-years (boys 13,8, girls 9,2) Figure 5 shows 
crude incidence rates in Swiss residents; age at diagnosis 0-14 
years; period of diagnosis 1999-2018; all diagnoses (ICCC-3 
but not including Langerhans cell histiocytosis); Figure 6 shows 
age- and sex-specific incidence rates for age 0-14).
   Relative Sex ratio Age at Dx 
 Diagnosis n frequency (male:female) (Median) Incidence*
I Leukaemias, myeloproliferative diseases, and myelodysplastic diseases 686 32.3 1.6 4.9 5.6
 a. Lymphoid leukaemias 546 79.6 1.5 4.8 4.4
 b. Acute myeloid leukaemias 83 12.1 1.7 6.3 0.7
 c. Chronic myeloproliferative diseases 14 2.0 2.5 12.4 0.1
 d. Myelodysplastic syndrome and other myeloproliferative diseases 36 5.2 3.0 4.3 0.3
 e. Unspecified and other specified leukaemias 6 0.9 0.2 1.0 0.0
II Lymphomas and reticuloendothelial neoplasms 214 10.1 1.9 10.9 1.7
 a. Hodgkin lymphomas 90 42.1 1.0 12.6 0.7
 b. Non-Hodgkin lymphomas (except Burkitt lymphoma) 64 29.9 1.9 8.7 0.5
 c. Burkitt lymphoma 55 25.7 8.2 8.1 0.4
 d. Miscellaneous lymphoreticular neoplasms 5 2.3 0.7 2.8 0.0
 e. Unspecified lymphomas 0 NA NA NA NA
III CNS and miscellaneous intracranial and intraspinal neoplasms 508 23.9 1.2 6.6 4.1
 a. Ependymomas and choroid plexus tumour 59 11.6 1.8 4.6 0.5
 b. Astrocytoma 203 40.0 1.0 6.4 1.7
 c. Intracranial and intraspinal embryonal tumour 85 16.7 1.4 6.1 0.7
 d. Other gliomas 74 14.6 0.8 7.5 0.6
 e. Other specified intracranial and intraspinal neoplasms 75 14.8 1.3 9.7 0.6
 f. Uspecified intracranial and intraspinal neoplasms 11 2.2 2.7 2.7 0.1
IV Neuroblastoma and other peripheral nervous cell tumours 142 6.7 1.3 1.6 1.2
 a. Neuroblastoma and ganglioneuroblastoma 140 98.6 1.3 1.6 1.1
 b. Other peripheral nervous cell tumours 2 1.4 NA 10.3 0.0
V Retinoblastoma 48 2.3 1.1 0.9 0.4
VI Renal tumours 99 4.7 1.0 3.2 0.8
 a. Nephroblastoma and other nonepithelial renal tumours 96 97.0 1.0 3.2 0.8
 b. Renal carcinomas 3 3.0 2.0 8.5 0.0
 c. Unspecified malignant renal tumours 0 NA NA NA NA
VII Hepatic tumours 21 1.0 2.5 2.1 0.2
 a. Hepatoblastomas 18 85.7 2.6 2.1 0.1
 b. Hepatic carcinomas 3 14.3 2.0 8.9 0.0
 c. Unspecified malignant hepatic tumours 0 NA NA NA NA
Table 5 
Childhood cancer diagnosed in Switzerland 2009 - 2018: number of cases, relative frequency, sex ratio, median age at diagnosis, and 
incidence standardised according to the Swiss standard population, by diagnostic groups according to ICCC - 3
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   Relative Sex ratio Age at Dx 
 Diagnosis n frequency (male:female) (Median) Incidence*
VIII Malignant bone tumours 80 3.8 0.8 11.8 0.7
 a. Osteosarcomas 44 55.0 0.9 11.8 0.4
 b. Chondrosarcomas 2 2.5 1.0 12.7 0.0
 c. Ewing tumour and related sarcomas of bone 33 41.3 0.8 11.7 0.3
 d. Other specified malignant bone tumours 0 NA NA NA NA
 e. Unspecified malignant bone tumours 2 2.5 1.0 12.7 0.0
IX Soft tissue and other extraosseous sarcomas 149 7.0 1.0 7.2 1.2
 a. Rhabdomyosarcomas 77 51.7 0.9 4.5 0.6
 b. Fibrosarcomas, peripheral nerve sheath tumours, and other fibrous neoplasms 10 6.7 2.3 9.4 0.1
 c. Kaposi sarcoma 0 NA NA NA NA
 d. Other specified soft tissue sarcomas 47 31.5 0.7 10.6 0.4
 e. Unspecified soft tissue sarcomas 14 9.4 2.5 9.0 0.1
X Germ cell tumours, trophoblastic tumours, and neoplasms of gonads 68 3.2 0.9 10.0 0.6
 a. Intracranial and intraspinal germ cell tumours 24 35.3 2.0 11.2 0.2
 b. Malignant extracranial and extragonadal germ cell tumours 19 27.9 0.5 0.1 0.2
 c. Malignant gonadal germ cell tumours 24 35.3 0.7 11.8 0.2
 d. Gonadal carcinomas 0 NA NA NA NA
 e. Other and unspecified malignant gonadal tumours 1 1.5 NA 0.8 0.0
XI Other malignant epithelial neoplasms and malignant melanomas 103 4.8 0.6 12.7 0.8
 a. Adrenocortical carcinomas 4 3.9 0.3 5.1 0.0
 b. Thyroid carcinomas 17 16.5 0.1 13.4 0.1
 c. Nasopharyngeal carcinomas 2 1.9 1.0 13.6 0.0
 d. Malignant melanomas 11 10.7 0.2 13.3 0.1
 e. Skin carcinomas 8 7.8 1.0 12.0 0.1
 f. Other and unspecified carcinomas 63 61.2 0.9 12.6 0.5
XII Other and unspecified malignant neoplasms 6 0.3 1.0 7.2 0.0
 a. Other specified malignant tumours 3 50.0 0.5 3.6 0.0
 b. Other unspecified malignant tumours 1 16.7 NA 0.0 0.0
Total (not including Langerhans cell histiocytosis) 2124 100.0 1.3 6.2 17.3
 Langerhans cell histiocytosis 67 3.1 1.7 5.8 0.5
Total (including Langerhans cell histiocytosis) 2191 100.0 1.3 6.2 17.8
 
* Incidence: newly diagnosed tumours in a one years time period per 100‘000 persons (person-years); NA: not applicable
Swiss residents; age at diagnosis 0-14 years, period of diagnosis 2009-2018, all diagnoses (ICCC-3 or Langerhans cell histiocytosis); N=2191
Table 5 Continued
20
Figure 6
Age-  and sex- specific incidence 
rates (per 100'000 person- years) in 
Switzerland for the last 10 years
Swiss residents; age at diagnosis 0-14 years; 
period of diagnosis 2009-2018; all diagnoses 
(ICCC-3 but not including Langerhans cell 
histiocytosis); N=2124
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Figure 5
Crude incidence rate 
(per 100'000 person-years) in Switzer-
land, by sex and year of diagnosis 
for the last 20 years (1999-2018)
Swiss residents; age at diagnosis 0-14 years; 
period of diagnosis 1999-2018; all diagnoses 
(ICCC-3 but not including Langerhans cell 
histiocytosis); N=4039
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3.4 Swiss residents aged 15 - 20 years 
 at diagnosis (N = 940)
Table 6 describes the tumours registered in the last ten 
years (2009 - 2018) diagnosed in adolescent patients (aged 
15 - 20 years at diagnosis, N = 940). Because data on adoles-
cents are currently not complete within the SCCR, we do not 
present incidence rates. In adolescents the sex ratio is closer to 
1 than in those aged 0 - 14 years at diagnosis. 
    Relative Sex ratio Age at Dx 
 Diagnosis n frequency (male:female) (Median)
I Leukaemias, myeloproliferative diseases, and myelodysplastic diseases  102 10.9 1.2 17.2
 a. Lymphoid leukaemias  52 51.0 1.6 16.8
 b. Acute myeloid leukaemias  25 24.5 0.9 17.7
 c. Chronic myeloproliferative diseases  14 13.7 0.8 18.1
 d. Myelodysplastic syndrome and other myeloproliferative diseases  10 9.8 1.0 16.4
 e. Unspecified and other specified leukaemias  1 1.0 NA 15.1
II Lymphomas and reticuloendothelial neoplasms  223 23.8 1.3 17.7
 a. Hodgkin lymphomas  147 65.9 1.2 17.6
 b. Non-Hodgkin lymphomas (except Burkitt lymphoma)  62 27.8 1.4 17.8
 c. Burkitt lymphoma  12 5.4 5.0 17.8
 d. Miscellaneous lymphoreticular neoplasms  1 0.4 NA 20.0
 e. Unspecified lymphomas  1 0.4 NA 15.3
III CNS and miscellaneous intracranial and intraspinal neoplasms  124 13.2 1.3 17.5
 a. Ependymomas and choroid plexus tumour  14 11.3 6.0 19.4
 b. Astrocytoma  37 29.8 0.9 18.1
 c. Intracranial and intraspinal embryonal tumours  19 15.3 1.4 16.8
 d. Other gliomas  18 14.5 0.5 17.3
 e. Other specified intracranial and intraspinal neoplasms  33 26.6 1.5 17.3
 f. Uspecified intracranial and intraspinal neoplasms  3 2.4 2.0 16.9
IV Neuroblastoma and other peripheral nervous cell tumours  5 0.5 0.7 18.5
 a. Neuroblastoma and ganglioneuroblastoma  1 20.0 NA 16.3
 b. Other peripheral nervous cell tumours  4 80.0 1.0 19.2
V Retinoblastoma  0 NA NA NA
VI Renal tumours  4 0.4 3.0 16.4
 a. Nephroblastoma and other nonepithelial renal tumours  1 25.0 NA 16.4
 b. Renal carcinomas  3 75.0 2.0 16.4
 c. Unspecified malignant renal tumours  0 NA NA NA
VII Hepatic tumours  2 0.2 2.0 18.5
 a. Hepatoblastomas  0 NA NA NA
 b. Hepatic carcinomas  2 100.0 2.0 18.5
 c. Unspecified malignant hepatic tumours  0 NA NA NA
VIII Malignant bone tumours  65 6.9 1.6 16.7
 a. Osteosarcomas  40 61.5 1.4 16.7
 b. Chondrosarcomas  7 10.8 6.0 19.8
 c. Ewing tumour and related sarcomas of bone  18 27.7 1.6 16.4
 d. Other specified malignant bone tumours  1 1.5 NA 17.4
 e. Unspecified malignant bone tumours  0 NA NA NA
Table 6 
Adolescent cancer diagnosed in Switzerland 2009-2018: number of cases, relative frequency, sex ratio, and median age at diagnosis 
by diagnostic groups according to ICCC-3
22
Table 6 Continued
    Relative Sex ratio Age at Dx 
 Diagnosis n frequency (male:female) (Median)
IX Soft tissue and other extraosseous sarcomas  69 7.4 1.6 17.7
 a. Rhabdomyosarcomas  15 21.7 1.5 17.5
 b. Fibrosarcomas, peripheral nerve sheath tumours, and other fibrous neoplasms  14 20.3 2.5 16.6
 c. Kaposi sarcoma  0 NA NA NA
 d. Other specified soft tissue sarcomas  32 46.4 1.5 18.4
 e. Unspecified soft tissue sarcomas  8 11.6 1.0 17.5
X Germ cell tumours, trophoblastic tumours, and neoplasms of gonads  118 12.6 4.1 18.7
 a. Intracranial and intraspinal germ cell tumours  10 8.5 10.0 17.0
 b. Malignant extracranial and extragonadal germ cell tumours  1 0.8 NA 20.9
 c. Malignant gonadal germ cell tumours  98 83.1 5.1 18.9
 d. Gonadal carcinomas  7 5.9 0.2 19.0
 e. Other and unspecified malignant gonadal tumour  2 1.7 1.0 17.9
XI Other malignant epithelial neoplasms and malignant melanomas  219 23.4 0.5 18.5
 a. Adrenocortical carcinomas  1 0.5 NA 15.1
 b. Thyroid carcinomas  60 27.4 0.3 17.7
 c. Nasopharyngeal carcinomas  4 1.8 3.0 20.0
 d. Malignant melanomas  52 23.7 0.9 19.0
 e. Skin carcinomas  16 7.3 1.0 19.0
 f. Other and unspecified carcinomas  85 38.8 0.4 18.4
XII Other and unspecified malignant neoplasms  5 0.5 1.5 17.4
 a. Other specified malignant tumours  5 100.0 1.5 17.4
 b. Other unspecified malignant tumours  0 NA NA NA
Total (not including Langerhans cell histiocytosis)  936 100 1.2 17.8
Langerhans cell histiocytosis  4 0.4 1.0 17.8
Total (including Langerhans cell histiocytosis)  940 100 1.2 17.8
Swiss residents; age at diagnosis 15-20 years, period of diagnosis 2009-2018, all diagnoses (ICCC-3 or Langerhans cell histiocytosis); N=940
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4. Research on childhood cancer
The research of the childhood cancer registry focusses on 
two main topics: Aetiology of childhood cancer and longterm 
outcomes and follow-up care. These topics are described with 
their background, aims, methods, recent findings, ongoing 
studies, and contacts in the remainder of Chapter 4. Addi-
tional information is available from the investigators and our 
website (www.childhoodcancerregistry.ch). Further, we thank 
the supporters for their generous contributions towards the 
research projects.
All previous and ongoing studies, their funding sources, 
and the senior investigator are summarized in Table 7.
Table 7
Research grants of the SCCR, summary
 No Project name Senior investigator Funding sources Study period   
Aetiology of childhood cancer
 1 Low dose ionising radiation and the risk of childhood cancer  Spycher BD Swiss National Science Founda- 10.2017-09.2021
     tion (SNF 320030_176218/1)  
 2 Residential and occupational exposure to UV radiation  Spycher BD Swiss Cancer Research  01.2019-12.2021
  and haematological malignancies  (KLS-4592-08-2018) 
 3 Spatial variation of childhood cancer risk in Switzerland and Spycher BD Swiss Cancer Research 01.2017-12.2018 
  associations with traffic-related air pollution   (KFS-4012-08-2016)
 4 Spatial and spatio-temporal clustering of childhood cancer:  Spycher BD Swiss Cancer Research 01.2014-12.2016 
  The role of infections and environmental hazards   (KFS-3515-08-2014)
 5 The spatial epidemiology of childhood cancer in Switzerland  Spycher BD Swiss Cancer Research 01.2014-12.2016
    (KFS-3515-08-2014) 
 6 The role of population mixing and exposure to infections in Spycher BD Swiss Cancer Research 01.2013-12.2014
  the aetiology of childhood leukaemia: a national cohort study  (KFS-3049-08-2012)
 7 Childhood cancer and geographically defined exposures  Spycher BD Federal Office of Public Health 03.2013-11.2013
  in Switzerland: a census-based nationwide cohort study  (12.008357) 
 8 Childhood cancer and vicinity of residence to petrol stations  Kuehni CE Federal Office of Public Health  06.2010-02.2013
  and roads: census-based nationwide cohort study (PETROL)  (10.002946) 
 9 Childhood cancer and nuclear power plants in Switzerland:  Kuehni CE Swiss Cancer League  09.2008-02.2011
  A census-based cohort study  (02224-03-2008);
    Federal Office of Public Health
    (08.001616)
Outcome research (Long - term outcomes, follow - up care, international collaboration)
 1 Swiss Childhood Cancer Survivor Study (SCCSS) Kuehni CE Kinderkrebshilfe Schweiz 01.2006-12.2018
   Kuehni CE Stiftung zur Krebsbekämpfung  01.2017-12.2017
   Kuehni CE, Angst R Cancer League Aarau 01.2012-12.2012
    Kuehni CE,  Cancer League Zurich  08.2010-07.2011
   Bergstraesser E
    Kuehni CE Cancer League Bern  04.2009-03.2010
    Von der Weid NX,  Swiss Cancer League  07.2008-06.2010
   Kuehni CE (KLS-2215-02-2008) 
    Von der Weid NX,  Swiss Cancer League 01.2006-10.2008
   Kuehni CE (KLS-1605-10-2004)   
 2  Pulmonary dysfunction after childhood cancer: diagnosing  Kuehni CE Swiss Cancer Research 09.2017-08.2020
  cearly stage disease  (KFS-4157-02-2017)  
 3 PanCare Studies in Fertility and Ototoxicity to improve  Kuehni CE EU (FP7- 11.2013-10.2018
  Quality of Life after Cancer during Childhood, Adolescence   HEALTH-F2-2013- 602030)
  and Young Adulthood (PanCareLIFE) Kuehni CE Swiss Cancer League  07.2014-06.2017
    (KLS-3412-02-2014) 
 4 PanCare childhood and adolescent cancer survivor care Kuehni CE EU (FP7- 02.2011-01.2017
  and follow-up studies (PanCareSurFup)   HEALTH-F2-2010-257505)
   Kuehni CE Swiss Cancer Research  08.2011-07.2014
    (KFS-02783-02-2011)  
 5 Mortality after cancer in childhood and adolescence  Kuehni CE Swiss National Science  08.2012-08.2015
    Foundation (PDFMP3_141775)  
   Kuehni CE Swiss Bridge 07.2012-07.2014
 6 The Swiss Pediatric Hematology/Oncology Metabank  Bourquin JP, Kuehni CE, Swiss National Science   04.2019-03.2021
  – a network for precision medicine research Ansari M Foundation (31BL30_185396) 
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 No Project name (continued) Senior investigator Funding sources Study period   
 7 Cardiovascular disease after childhood cancer:  Von der Weid NX,  Swiss Cancer League 01.2017-12.2019
  diagnosing early stage disease Kuehni CE (KLS-3886-02-2016) 
 8 Dietary habits, nutrition and risk of late effects Bochud M, Kuehni CE Swiss Cancer League 07.2015-06.2018 
  after childhood cancer  (KLS-3644-02-2015) 
 9 Dietary intake, overweight, and late effects development in  Bochud M, Kuehni CE  Swiss Cancer Research 07.2019-06.2022
  childhood cancer survivors   (KFS-4722-02-2019)
 10 Risk of cancer and long-term mortality in children treated  Mullis P EU 04.2011-03.2014
  with growth hormone: Swiss participation in the EU FP7   (FP-HEALTH-F2-2009-223497)
  project (SAGhE) Mullis P, Kuehni CE  Swiss Cancer League 07.2012-12.2013
    (KLS-2948-02-2012)
   Mullis P, Kuehni CE Swiss Cancer League  07.2010-12.2012
    (KLS-02586-02-2010) 
 11 Lung problems after childhood cancer: Implementation  Sommer G Kinderkrebs Schweiz 06.2017-05.2018
  of a structured follow-up care in Switzerland  
 12 Pulmonary late-effects in long-term childhood cancer  Sommer G, Goutaki M Cancer League Bern  01.2017-02.2018
  survivors – Development of guidelines for follow-up care  Lung League Bern 
 13 Improving follow-up care of childhood cancer:  Michel G,  Swiss Cancer Research 04.2017-03.2020
  implementation of screening for psychological distress Scheinemann K (KFS-3955-08-2016) 
 14 PanCareFollowUp: Novel, patient-centred survivorship Michel G Horizon 2020 01.2019-12.2023
  care to improve care quality, effectiveness, cost-effective-  (SEP-210494581)
  ness and accessibility for survivors and caregivers     
 15 Grandparents’ involvement and psychosocial outcomes  Michel G Swiss National Science  01.2019-12.2022
  when a grandchild is diagnosed with cancer: acute and   Foundation
  long-term consequences   (10001C_182129/1)
 16 Needs for psychosocial care after childhood cancer Michel G Swiss Cancer Research 06.2017-05.2019
  – A mixed methods study  (HSR-4080-11-2016) 
 17 Psychological late effects in long-term childhood cancer  Michel G Krebsliga Zentralschweiz 11.2015-10.2017
  survivors – Development of guidelines for follow-up care 
 18 Follow-up care after childhood and young adult  Michel G Swiss National Science  08.2009-08.2014
  cancer (CCFU)   Foundation (PZ00P3_121682 
    and PZ00P3_141722) 
 19 Effectiveness of transition from paediatric to adult care  Michel G Swiss Cancer League 04.2011-04.2014
  after childhood cancer  (KFS-02631-08-2010) 
 20 Parents of long-term childhood cancer survivors Michel G Swiss National Science Foun-  since 2013
    dation (100019_153268/1) 
    Kinderkrebshilfe Schweiz 
 21 Fertility after Chemo- and Radiotherapy in Childhood and  Michel G Kinderkrebshilfe Schweiz since 2012
  Adolescence, FeCt – Multicentre 
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4.1 Aetiology of childhood cancer
 Background
The aetiology of childhood cancers remains largely un-
known. For leukaemia, the most frequent childhood cancer, 
known risk factors include trisomy 21, certain rare genetic 
syndromes, some common germline genetic variants, high 
birthweight, and high parental age at birth. Regarding envi-
ronmental exposures, only ionising radiation at medium to 
high doses is an established risk factor – both for leukaemia 
and CNS tumours. Numerous other environmental factors are 
being discussed as potential risk factors. These include: low 
dose ionising radiation (e.g. natural background radiation and 
diagnostic radiation), traffic related air pollution, electromag-
netic fields (e.g. from power lines, radio and TV transmitters, 
or mobile phones) pesticides, and infections.
 Aims
The broad aims of the group are to investigate: 
• Whether cancer risks in children are associated with 
environmental exposures, such as ionising and non-ion- 
ising radiation, air pollution, and UV exposure, as well as 
parents workplace exposures;
• Whether cancer risks in children are associated with 
socio-economic, family or perinatal exposures;
• The spatial and spatio-temporal distribution of childhood 
cancer cases in order to identify potential environmental 
risk factors.
 Methods
Clinical and residential information on diagnosed cases 
are obtained from the SCCR. Data on the population at risk 
are obtained from the Swiss National Cohort (SNC) which 
includes the entire Swiss resident population at census time 
points (1990, 2000, and annually from 2010 onward). Record 
linkage between the two datasets allows investigating cancer 
incidence on a nationwide scale with a cohort design. The 
SCCR collects geocoded address histories from birth to diag-
nosis allowing to distinguish different exposure time windows. 
Geocoded places of residence are also available for the entire 
population from the SNC. This allows calculating geographically 
determined exposures such as distance to highways or NO
2 
concentration levels (based on spatial pollution models) for the 
entire population at risk. The SNC also provides demographic, 
socioeconomic and perinatal data for the entire population. 
The availability of precise geocodes of residence allows investi-
gating spatial and spatio-temporal clustering or identifying areas 
of higher risk (disease mapping) using methods for point pat-
tern data rather than methods for less precise regional count 
data (e.g. aggregated at municipality level).
 Current status
A, Recent findings: A summary of our recent research and 
findings is given in [Lupatsch-2016a]. We found evidence of in- 
creased risks of childhood leukaemia and CNS tumours among 
children exposed to higher levels of natural background radia- 
tion (terrestrial gamma and cosmic radiation) [Spycher-2015a, 
2015b, 2015c]. Young children living in the immediate prox- 
imity (<100m) of highways were found to have an increased 
leukaemia risk [Spycher-2015d]. We found little evidence of 
associations between childhood leukaemia and commonly 
used measures of population mixing [Lupatsch-2015b, c] or for 
associations between leukaemia risk and socioeconomic status 
[Adam-2015]. However, we did find evidence of a temporal 
association between childhood leukaemia and periods of rapid 
population growth in Swiss municipalities [Lupatsch-2016d]. 
We found evidence for spatio-temporal clustering of leukae- 
mia around the time of birth but not around the time of diag- 
nosis [Kreis-2016] and this clustering was associated with the 
TEL-AML1 (ETV6-RUNX1) cytogenetic subtype [Kreis-2017]. In 
contrast, we found little evidence of purely spatial clustering 
for childhood leukaemia [Konstantinoudis-2017], but some 
evidence for embryonal CNS tumours and Hodgkin lymphoma 
[Konstantinoudis-2018]. In an international pooled analysis we 
found a small but imprecise risk for proximity to powerlines 
and childhood leukaemia that was not explained by high mag-
netic fields [Amoon-2018]. In a recent systematic review, we 
found evidence of space-time clustering of childhood leukae-
mia around time of diagnosis among children aged 0-5 years 
[Kreis-2019].
B, Ongoing studies: In ongoing studies we are investigat- 
ing whether: i) childhood cancer is associated with increased 
air concentrations of benzene and NO
2
; ii) childhood leukae- 
mia is associated with perinatal characteristics (including pa- 
rental age, birth order, age difference to next older sibling, 
and birth weight); iii) there are specific areas of increased risk 
of childhood cancers in Switzerland (disease mapping); and iv) 
the role of UV exposure with respect to haematological malig-
nancies. v) We are also conducting a nationwide survey com-
plemented with dosimetry measurements to retrieve precise 
estimates of exposure to background radiation. This informa-
tion coupled with the background radiation statistical models 
we are developing will be used to assess association between 
background radiation and childhood cancer risk. Furthermore, 
we are vi) collaborating in an international case control study 
on the association between childhood cancer and proximity to 
transformers.
 Contact
The research team consists of Ben Spycher, Claudia Kuehni, 
Christian Kreis, Astrid Coste, Garyfallos Konstantinoudis, Chris-
tophe Folly, and Antonella Mazzei.
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4.2 Long- term outcomes
 Background
Childhood cancer is the most common disease-related 
cause of death in children in developed countries. Survival rates 
for childhood cancer now exceed 80% thanks to therapeutic 
improvements in the past decades [Schindler-2017], leading to 
a growing population of long-term survivors. However, can-
cer and its treatment can cause late effects, such as secondary 
neoplasms, heart and lung diseases, hearing loss, and infertility. 
Late effects may have an impact on survivors’ health, health be-
haviour and quality of life, and may lead to premature death. 
Comprehensive data on the burden of late effects of childhood 
cancer including premature mortality and their risk factors are 
scarce. The SCCR has a broad research program focusing on 
long-term outcomes including the national Swiss Childhood 
Cancer Survivor Study (SCCSS), prospective, clinical studies on 
lung and cardiovascular diseases, and a study on cause-specific 
long-term mortality. 
 Aims 
The research group aims to: 
• Investigate prevalence, incidence and spectrum of 
somatic and psychosocial outcomes including, somatic 
health, mental health, educational and social outcomes, 
health-related quality of life, secondary neoplasms, and 
cause-specific long-term mortality.
• Determine sociodemographic, cancer- and treatment 
related predictors associated with long-term outcomes.
• Describe health behaviours, and
• Investigate and improve follow-up care in childhood 
cancer survivors.
 Methods
Study population: Eligible are all individuals, who have been 
diagnosed with cancer at age <21 years, who survived at least 
five years, were alive at the time of the study, and who were Swiss 
residents at time of diagnosis. 
Collected data: We sent a detailed questionnaire to child-
hood cancer survivors and their parents to obtain data about 
somatic, psychosocial, lifestyle, and mental health outcomes. 
For comparison, we sent the same questionnaire excluding 
cancer-related questions to siblings of survivors. We complete 
and validate questionnaire data with phone interviews with 
patients, information from general practitioners, and hospi-
tal records, e.g. audiometric or lung function tests to validate 
hearing problems or lung diseases. We sent a second ques-
tionnaire to participating survivors to find out whether their 
health changes over time. We invite subgroups of survivors to 
paediatric oncology centres for clinical investigations to assess 
their lung and heart functions and we collect saliva and urine 
samples for genetic and metabolic analyses. Additionally, we 
gather data from municipal population registries to obtain vital 
status and date of death, and from Swiss mortality statistics to 
obtain causes of death. This broad approach makes it possi-
ble to investigate prevalence and incidence of late effects and 
causes of death in Swiss survivors and to identify predictors for 
their occurrence.
Response rate: For the SCCSS questionnaire survey, we 
contacted 4689 five-years survivors aged 0-<20 years at diag- 
nosis, 3177 (68%) completed our questionnaire. Among the 
participating survivors, we contacted 1599 survivors with a 
second questionnaire, of whom 919 (57%) responded. We 
also contacted 1530 siblings of childhood cancer survivors, of 
which 866 (57%) participated.
 Current status
A, Recent findings
These ongoing studies provide national data on late effects, 
health behaviour, survival and long-term mortality, and causes 
of death after childhood and adolescence cancer in Switzerland. 
We analyse data and publish our findings continuously. Previous 
publications reported on health-related quality of life, educa-
tion, cognitive problems, partnership, income, physical activity, 
lung disease, cardiovascular disease, hearing loss, nutrition, 
overweight, survival, and mortality. Our findings help to identify 
patients who are at risk for late effects, to adjust therapies, and 
to develop tailored follow-up programs for survivors.
Health- related quality of life (HRQoL): We found that the 
overall HRQoL of young survivors (8-16 years) was comparable 
to population norms for most parent- reported dimensions and 
higher for most self-reported dimensions [Wengenroth-2015]. 
However, older survivors (>16 years) had lower HRQoL than 
their siblings, and among survivors, those with chronic health 
problems had the lowest health-related quality of life [Rueegg-
2013]. Even after a relapse, survivors of acute lymphoblastic 
leukemia reported a good HRQoL [Essig-2012].
Educational and social outcomes: We showed that sur-
vivors achieved educational levels similar to the general pop-
ulation [Kuehni-2012]. Survivors younger than 20 years were 
more likely to report cognitive problems than their siblings 
[Wengenroth-2015]. We found lower personal income in sur-
vivors than in siblings [Wengenroth-2016]. However, survivors’ 
personal income may increase later because treatment can 
push back education and carreer training and cause survivors 
to start working later than their peers. Survivors are less like-
ly than peers to be married or be in a life partnership [Wen-
genroth-2014]. Since survivors take longer to reach their final 
educational achievement than the general population [Kueh-
ni-2012], this might encourage survivors to delay marriage.
Physical activity: We found that daily physical activity 
and sport levels in survivors were similar to the general pop-
ulation. Physical activity was mainly determined by socio-de-
mographic and cultural factors [Rueegg-2012a]. However, 
we found that survivors are at high risk of suffering from 
performance limitations in sports and daily living activities 
but these limitations differed strongly between diagnostic 
groups [Rueegg-2012b]. Despite these physical performance 
limitations, many survivors maintained healthy activity levels 
[Rueegg-2013].
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Lung disease: Survivors are at increased risk of pneu-
monia, independent of treatment era. [Kasteler-2018b]. The 
number of survivors suffering from a pulmonary disease in-
creases with time after end of treatment. Therefore, long-term 
clinical monitoring of pulmonary health is necessary. But our 
results also show, that not all survivors exposed to lung toxic 
treatment modalities are followed up with pulmonary func-
tion tests in Switzerland [Kasteler-2018a]. The harmful effect 
of smoking to the lung can increase by the preceding lung 
toxic treatment. Despite this, we found that survivors who had 
lung toxic treatment did not smoke less than those who had 
not received such treatment. Overall survivors smoke as often 
as their siblings but less than the general population [Kastel-
er-2019]. 
Cardiovascular disease: Survivors of acute lymphoblastic 
leukemia are at increased risk for cardiovascular disease com-
pared to their sibings with the highest risk for heart failure. We 
found no risk reduction over time for cardiovascular disease, 
despite attempts to reduce cardiotoxicity of cancer treatment 
during past decades [Hau-2019]
Hearing loss: We found that the burden of hearing loss 
as a late effect after ototoxic cancer treatment has stabilized in 
recently treated survivors, suggesting that survivors have bene-
fited from new treatment regimens that use less ototoxic radi-
ation and carefully dosed platinum compounds [Weiss-2017]. 
We also found that questionnaires are useful to assess hearing 
in large cohorts of childhood cancer survivors, but they under-
estimate mild and unilateral hearing loss. [Weiss-2017]. Hear-
ing loss reduces physical well-being and impairs relationships 
with peers in survivors of CNS tumours, but not in other sur-
vivors [Weiss-2019]. Survivors may benefit from audiological 
monitoring, but guidelines are insufficiently followed in Swit-
zerland, particularly when patients neither are participants in a 
study nor treated according to a specific cancer study protocol 
[Weiss-2018].
Nutrition: We showed that young adults, who had cancer 
in childhood adhere poorly to national dietary recommenda-
tions [Belle-2017]. We assessed dietary intake by a food fre-
quency questionnaire and found that intake is similarly poor 
in Swiss childhood cancer survivors as in peers [Belle-2019b].
Overweight: We found that childhood cancer survivors 
in Switzerland are not more likely to become overweight than 
peers who had not had cancer [Belle-2018a, 2018b]. Cranial 
radiation leads to overweight that persists many years after 
diagnosis [Belle-2018b], but corticosteroid treatment is unlike-
ly to lead to overweight in the long-term [Belle-2018a]. Leu-
kaemia and lymphoma patients gained considerable weight 
during the duration of cancer treatment [Belle-2019a]. 
Survival: We found that five-year survival of children di-
agnosed with cancer in Switzerland improved from 64% in 
1976-1983 to 88% in 2004-2013, but there is room for fur- 
ther improvement. Survival rates varied by type of clinical treat- 
ment, language region, and nationality. To improve survival, all 
paediatric cancer patients should be referred to a specialised 
paediatric cancer centre [Schindler-2017].
Mortality: We found that five-year survivors of childhood 
cancers suffer from an elevated mortality compared to the 
general population, with recurrence and progression of the 
original cancer as the most common causes of death up to 24 
years after diagnosis [Schindler-2016].
 B, Ongoing studies 
Ongoing studies focus on different somatic health prob- 
lems and health behaviours: i) lung diseases; ii) cardiovascu-
lar diseases; iii) secondary neoplasms; and iv) dietary habits 
and overweight. We are currently setting up the collection 
of germline DNA of all childhood cancer patients and survi-
vors to allow research in cancer genetics. This germline DNA 
collection project is led jointly with the Children’s Hospitals 
in Zurich and Geneva under the «BioLink» research funding 
programme of the Swiss National Science Foundation. This 
project entitled «The Swiss Paediatric Haematology/Oncology 
Metabank» will link data from the SCCR with data from var-
ious biobanks. It aims to expand the already extensive data 
in the SCCR to include genetic and tumour information. The 
data in the biobanks on hereditary factors of the patients and 
their tumours, together with the clinical data, will enable in-
depth research in the fields of cancer predispositions, phar-
macogenetics, and genetic modifiers of long-term complica-
tions. This is an important step towards carrying out research 
in Switzerland to personalise childhood cancer treatment and 
aftercare. Furthermore, we collaborate in international stud-
ies (see International collaborations).
 Contact
The research team consists of Claudia Kuehni, Fabiën Belle, 
Maria Otth, Christina Schindera, Grit Sommer, Nicolas Waespe, 
and Nicolas von der Weid.
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4.3 International collaborations 
 Background
Late effects of childhood cancer and its treatment are 
common, but numbers in individual countries are low. There- 
fore, pooling observational data to large international cohorts 
and using genetic tools to analyse data are essential to iden-
tify risk factors. Survivors can benefit from personalized, evi-
dence-based care grounded on their individual risk; and future 
patients may benefit from adapted treatment, that cause less 
severe side effects.
International studies on childhood cancer often include 
systematic reviews that summarize the evidence of risk factors 
on late effects. These provide the basis for creating new guide-
lines for the clinical long-term follow-up of survivors.
The SCCR collaborates with other childhood cancer co-
horts [Bhatia-2015, Winther-2015, Tonorezos-2018], partic-
ipates in European studies to investigate late effects, and is 
involved in the development of international guidelines for 
clinical long-term follow-up of childhood and adolescent can-
cer survivors.
 Aims
Within the international collaborations, we aim to investigate:
• Prevalence and incidence of late effects of childhood and 
adolescent cancer and its treatment
• Risk factors for these late effects
• Follow-up care
We also aim to develop guidelines to improve the health 
and quality of life of current and future survivors of childhood 
cancer.
 Methods
Swiss survivors of childhood and adolescence cancer are 
part of the Pan-European Network for Care of Survivors af-
ter Childhood and Adolescent Cancer (PanCare). Researchers 
within this European collaboration can select survivors with 
late effects for nested case-control or case-cohort studies, for 
example survivors with secondary neoplasms, cardiovascular 
or hearing problems. Within these studies, researchers can 
identify non-genetic and genetic risk factors of late effects.
Experts and the International Guideline Harmonization 
Group (IGHG, http://www.ighg.org/) write systematic reviews 
to develop evidence-based, standardised guidelines for clinical 
follow-up of survivors.
 Current status
A, Ongoing studies:
Currently, we are collaborating in two ongoing studies:
PanCareSurFup (PanCare childhood and adolescent can-
cer survivor care and follow-up studies; http://www.pancare-
surfup.eu/) 
This project investigates the burden and risk factors of the 
most severe and life threatening late effects, namely secondary 
neoplasms, cardiovascular disease, and premature death. We 
contributed with 4719 Swiss five-year survivors to the Pan-Eu-
ropean cohort and with detailed treatment data from medical 
records of 139 Swiss survivors to the European nested-case 
control studies. 
Recent findings: PanCareSurFup published several articles 
[Feijen-2014, Terenziani-2014, Brown-2015, Hjorth-2015, Win-
ther-2015, Mulder-2016, Feijen-2016, Bright-2017, Fidler-2018, 
Grabow-2018, Byrne-2018] and more are in preparation.
PanCareLIFE (PanCare Studies in Fertility and Ototoxicity 
to Improve Quality of Life after Cancer during Childhood, Ad- 
olescence and Young Adulthood; http://www.pancarelife.eu/) 
This project investigates hearing loss, infertility and quality of 
life. We identified 304 survivors at risk for hearing loss and col-
lected their hearing tests. Among the 304 survivors, we con-
tacted 221 survivors for the collection of saliva samples and153 
survivors provided their saliva sample for the analysis of genetic 
risk factors for hearing loss. We contributed with SCCSS ques-
tionnaire data from 1585 survivors on hearing loss, fertility, and 
quality of life. Currently, we are analysing, together with the 
University of Bonn in Germany, quality of life data and its risk 
factors from 9871 survivors of five European countries. 
Recent findings: The first published articles describe the 
PanCareLIFE study design [Byrne-2018, van der Kooi-2018, van 
den Berg-2018, Clemens-2018]. Many more are in preparation. 
B, Development of guidelines
In close collaboration with experts worldwide and the 
International Guideline Harmonization Group (IGHG, http:// 
www.ighg.org /), we write systematic reviews and develop 
evidence-based, standardized guidelines for clinical follow-up 
of survivors. We are currently involved as chairs, work group 
(WG) leaders and group members in the development of the 
following guidelines: 
l Hearing loss (ototoxicity)
 • Chairs: Wendy Landier (USA), Richard Cohn (AUS)
 • WG leaders: Claudia Kuehni (CH), Thorsten Langer (DE)
l  Pulmonary dysfunction
 • Chairs and WG leaders: Claudia Kuehni (CH), 
   Andrew Dietz (USA)
l Fatigue, mental health and psychosocial problems
 • Chairs: Gisela Michel (CH), Jordan Gilleland Marchak (USA)
 • Fatigue WG leaders: Kathrin Scheinemann (CH), Gisela  
 Michel (CH)
 • Mental Health WG leaders: Janine Vetsch (CH), Jordan  
 Gilleland Marchak (USA)
 • Psychosocial WG leaders: Katie Devine (USA), Martha  
 Grootenhuis (NL)
l Metabolic syndrome-Obesity
 • Obesity WG leaders: Kevin Oeffinger (USA), Emily Ton- 
 orezos (USA)
l Hypothalamic-Pituitary disorders 
 • Chairs: Hanneke van Santen (NL), Wassim Chemaitilly (US) 
Recent findings: A survey among paediatric oncology/ 
haematology clinics from 44 European countries found that 
many clinics have insufficient or lack programmes for long-term 
follow-up into adulthood for survivors of childhood cancer 
[Brown-2015]. This study showed that available guidelines are 
not universally used throughout Europe and we need to further 
develop and disseminate Pan-European long-term follow-up 
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guidelines. Recommendations for ototoxicity surveillance for 
childhood, adolescent, and young adult cancer survivors with-
in IGHG are recently published [Clemens-2019].
4.4 Psychosocial outcomes and follow-up care
 Background
Treatment for cancer in children, adolescents and young 
adults has improved remarkably and most patients can be cured 
today. However, more than 50% of survivors of childhood can-
cer suffer from late effects. To detect and treat late effects as 
early as possible, most survivors should continue to attend fol-
low-up care long after their cancer has been cured. Follow-up 
care needs to be constantly updated to meet the current sta-
tus of research. International guidelines summarising the care 
needed after different cancers and treatment are necessary. 
Additionally, while various models of follow-up care have been 
described, so far none has been implemented in Switzerland. A 
successful model must not only take clinical aspect into account 
but also survivors’ preferences and needs. A childhood cancer 
diagnosis does not only affect the child, but the whole family 
system. Parents might be affected long after their child has been 
cured. However, there is lack of research on how parents of 
childhood cancer are doing in the very long-term.
 Aims
The group aims to:
• Describe follow-up care models available across Europe, 
and preferences for a follow-up model among Swiss 
childhood, adolescent and young adult cancer survivors, 
parents and physicians (oncologists and general practi-
tioners)
• Evaluate the transition/transfer from paediatric to adult 
care in survivors of childhood cancer
• Develop guidelines on psychosocial aspects of follow-up 
care
• Describe psychological and socio-economic outcomes, 
as well as needs in survivors of childhood, adolescent 
and young adult cancer and their family (with a focus on 
parents of very long-term survivors and grandparents)
 Methods
To describe follow-up care models in Europe, we invited 
198 clinics and follow-up programmes in Europe to complete 
a questionnaire survey describing the follow-up care available 
at their institution. To assess preferences for different models 
of follow-up care, a questionnaire survey assessed opinions and 
perspectives on both currently used and desired optimal fol-
low-up care among survivors, parents, paediatric and adult on-
cologists/haematologists and family practitioners. We evaluated 
the transition from paediatric to adults among childhood cancer 
survivors using medical records. Guidelines are being developed 
in collaboration with the IGHG. Furthermore, we contacted 
parents of childhood cancer survivors in a questionnaire survey 
to assess positive and negative psychological, familial, and so-
cio-economic outcomes. These outcomes are compared to the 
Swiss general population.
 Current status
A, Recent Findings: 
Follow-up care: Our survey among European paediatric 
oncology/haematology clinics found that many still are lacking 
programmes for long-term follow-up into adulthood [Essig-2012, 
Brown-2015]. Additionally, a large proportion of Swiss survivors
do not attend regular follow-up care [Michel-2011, Rebholz-
2011, Lupatsch-2016e]. We found supportive subjective norms 
being associated with the intention to attend follow-up care 
and the intention being associated with actual attendance of 
follow-up care in childhood as well as adolescent and young 
adult cancer survivors [Baenziger-2018, Roser-2018]. Further-
more, in adolescent and young adult cancer survivors, also pos-
itive attitudes towards follow-up care were associated with the 
intention to attend follow-up care [Roser-2018]. Survivors and 
their parents desire precise information on late effects and fol-
low-up care [Gianinazzi-2014a, Vetsch-2015, 2017b]. Most sur-
vivors and parents reported preferences for care by a specialist 
(oncologist) [Vetsch-2016, Christen-2016, Vetsch-2017, 2018]. 
Transition: In Switzerland, there is no specialised transition 
programme for survivors of childhood cancer from paediatric 
to adult care. We investigated if patients are receiving e.g. fol-
low-up information after release from the paediatric oncology 
clinic [Gianinazzi-2015]. Patient-adapted information on diag-
nosis, treatment and future follow-up, provided at the time 
of discharge, was rarely found. Physicians providing follow-up 
care reported a need for guidelines and better organisation of 
transition to adult care (Michel-2017, Essig-2019). Guidelines 
for transition have been developed (Mulder-2016).
Psychological late effects: We found that both, survivors 
of childhood as well as adolescent and young adult cancer, are 
at increased risk for psychological distress [Gianinazzi-2013, Gi-
aninazzi-2014b, Michel-2015, Gianinazzi-2016, Michel-2019] 
or other negative psychosocial outcomes [Wengenroth-2014, 
2015a, 2015b, Kuehni-2012a, Rebholz-2012, Mader-2017a, 
2017c, Brinkman-2018]. Survivors of adolescent and young 
adult cancer reported worse physical health compared to the 
Swiss general population [Harju-2018]. Male survivors report-
ed better mental health and females slightly worse. The pro-
portions of survivors with poor physical health or poor mental 
health did not differ from these proportions in the general pop-
ulation. 
Parents of long-term childhood cancer survivors: Parents 
of survivors were less often divorced or separated and more of-
ten in a partner relationship compared to parents of the Swiss 
general population [Mader-2019]. Not being married was not 
associated with cancer-related characteristics. Parents of sur-
vivors reported similar security but higher dependency within 
the partner relationship compared to parents of the general 
population.
 B, Ongoing studies: 
The study on parents of childhood cancer survivors is the 
first population-based study among parents of long-term survi-
vors of childhood cancer. Data collection has been completed 
and the upcoming analyses will shed more light on their psy-
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chological well-being, socio-demographic outcomes and the 
needs they have for their children and themselves.
 Contact
The research team consists of Gisela Michel, Julia Bänziger, 
Salome Christen, Manya Hendriks, Anica Ilic, Cristina Priboi, 
and Katharina Roser in close collaboration with Claudia 
Kuehni, Katrin Scheinmann, Eva Maria Tinner, and Nicolas 
von der Weid.
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All articles published using SCCR data from January 2007 – 
March 2019 are reported below. Additional publications related 
to the SCCR or SPOG can be found on the SCCR and SPOG 
websites: www.childhoodcancerregistry.ch and www.spog.ch.
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International Classification of Childhood Cancer  - 
ICCC - 3
The third edition of the International Classification of 
Childhood Cancer (ICCC - 3) represents the standard for pre-
sentation of international data on childhood cancer incidence 
and survival. It applies the rules, nomenclature and codes (mor-
phology, topography and behaviour) of the ICD - O - 3. ICCC - 3 
categories are defined in conformity with international classifi-
cations of the pathology and genetics of childhood cancers. In 
the ICCC - 3, three hierarchical levels have been developed: lev-
el one consists of 12 main diagnostic groups and level two of 
47 diagnostic subgroups. These two levels of the ICCC - 3 allow 
standardised comparison of the broad categories of childhood 
tumours. Level three, an optional «extended» classification, 
comprises two to eleven divisions of selected diagnostic sub-
groups. The division of some diagnostic subgroups, e.g. leu-
kaemia and Non - Hodgkin lymphomas, reflects the availability 
of detailed cytogenetic or molecular information that permits 
homogeneous groups of tumours to be distinguished within 
them and thus allows their separate study. The Swiss childhood 
cancer registry (SCCR) uses level one to three. Only malignant 
neoplasms are classified in ICCC - 3, with the exception of 
non - malignant intracranial and intraspinal tumours. Tumours 
known to occur only rarely in young patients are also included 
in ICCC - 3. The ICCC - 3 is used if data are compared with other 
childhood cancer registries.
International Statistical Classification of Diseases for 
Oncology  - ICD - O - 3
The third edition of the International Statistical Classifica-
tion of Diseases for Oncology (ICD - O - 3) has been developed 
by a working group hosted by the International Association of 
Research in Cancer (IARC) and WHO. The morphology code for 
neoplasm has been revised, especially for lymphomas and leu-
kaemia. In contrast to the International Classification of Diseas-
es, 10th revision (ICD - 10), ICD - O - 3 uses only one set of four 
characters for topography (based on the malignant neoplasm 
section of ICD - 10). The topography code remains the same for 
all neoplasms of that site. The behaviour code is incorporated 
as the fifth digit in the morphology field. It identifies whether 
the tumour is malignant, benign, of uncertain or unknown be-
haviour, in situ, presumed to be primary or secondary. For all 
tumours diagnosed since 1st January 2014 the SCCR uses the 
2011 updates to ICD - O - 3 which include new terms, codes 
and behaviour combinations. This allows e.g. B lymphoblas-
tic leukaemias to be further classified according to their exact 
cytogenetic and molecular characteristics, which are relevant 
for disease prognosis. ICD - O - 3 is used to compare data with 
general cancer registries.
International Statistical Classification of Diseases 
and Related Health Problems  - ICD - 10
The International Statistical Classification of Diseases and 
Related Health Problems (ICD) permits the systematic record-
ing, analysis, interpretation and comparison of mortality and 
morbidity data collected in different regions and at different 
time periods. The ICD has become the international standard 
diagnostic classification for all general epidemiological purpos-
es. The ICD - 10 classification comprises three volumes: Volume 
1 contains the main classifications; Volume 2 provides guid-
ance for users of the ICD; and Volume 3 is the alphabetical in-
dex to the classification. Classification is divided into 21 chap-
ters. The first character of the ICD code is a letter. Each letter 
is associated with a particular chapter, e.g. the letter D is used 
in both chapter II «Neoplasms» and chapter III «Diseases of the 
blood and blood - forming organs and certain disorders involv-
ing the immune mechanism». The topography code in Volume 
3 describes the site and the behaviour of the neoplasm: malig-
nant, secondary or metastatic, in situ, benign or of unknown 
behaviour. The morphology codes listed in Volume 1 are the 
same as those used in the special adaptation of the ICD for 
oncology, the ICD - O97.
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